Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 31

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 31
---
 any changes required by applicable law). Outstanding Shares and Purpose of the Proposal Our existing Certificate currently authorizes us to issue a maximum of 50,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of March 27, 2025, we had no shares of preferred stock issued and outstanding and the amendment of our Certificate will not affect the number of authorized shares of preferred stock. We currently have 40,222,872 shares of common stock either issued and outstanding or reserved for future issuance as follows:

| ● | 28,746,041 shares of common stock issued and outstanding; |

| ● | 5,680,487 shares of common stock issuable upon the exercise of warrants outstanding; |

| ● | 4,236,420 shares of common stock issuable upon the exercise of options outstanding; |

| ● | 91,149 shares of common stock issuable pursuant to restricted stock units outstanding; and |

| ● | 1,468,775 shares of common stock reserved for future grants, awards, and issuances under our current equity compensation plan. |

The approval of the Amendment to our Certificate to increase our authorized shares of common stock is important for our ongoing business. Our Board believes it would be prudent and advisable to have the additional shares available to provide additional flexibility regarding the potential use of shares of common stock for business and financial purposes in the future. Having an increased number of authorized but unissued shares of common stock would allow us to take prompt action with respect to corporate opportunities that develop, without the delay and expense of convening a special meeting of stockholders for the purpose of approving an increase in our authorized shares. The additional shares could be used for various purposes without further stockholder approval. These purposes may include: (i) raising capital, if we have an appropriate opportunity, through offerings of common stock or securities that are convertible into common stock; (ii) expanding our business through potential strategic transactions, including mergers, acquisitions, licensing transactions and other business combinations or acquisitions of new product candidates or products; (iii) establishing strategic relationships with other companies; (iv) exchanges of common stock or securities that are convertible into common stock for other outstanding securities; (v) providing equity incentives pursuant to our current equity incentive plans and any other plans we may adopt in the future, to attract and retain employees, officers or directors; and (vi) other general